New appointment at NormOxys
This article was originally published in Scrip
NormOxys, a US-based biotech company developing a class of small-molecule drugs which enhance the body's ability to deliver oxygen to diseased tissues, has named Dr Gerard Riedel vice-president of regulatory affairs and program management. He has more than 28 years' biopharmaceutical R&D experience, having previously served as vice-president of regulatory affairs at Momenta Pharmaceuticals. Before that, Dr Riedel was senior vice-president of regulatory affairs, quality assurance and project management at Praecis Pharmaceuticals.